Answers are grounded in this paper and cite their sources.
Candida species account for a large majority of fungal infections. The incidence of nosocomial fungal infections has been steadily increasing over recent years due to the increasing number of patients treated in intensive care units (ICU), the common administration of antimicrobial agents and the increasing use of invasive monitors. The route of infection in Candida pneumonia is endobronchial in cases of aspiration or haematogenous in patients with candidaemia. Because colonization of the lower respiratory tract with Candida is common, especially in the intubated and mechanically ventilated patient, the diagnosis cannot be established microbiologically. Even quantitative cultures of respiratory secretions cannot distinguish colonization from infection. Although serological markers of Candida infection or candidaemia are commercially available, the diagnosis of Candida pneumonia should only be derived from histological examination of lung tissue. According to the route of infection characteristic histological signs (e.g. budding yeast, pseudohyphae) can then be documented. Owing to the uncharacteristic clinical presentation of Candida pneumonia, early presumptive therapy has to be initiated in some cases. Amphotericin B remains the drug of choice in cases without bacteriological identification of the fungus, due to resistance of some non-albicans species against fluconazole. Patients with Candida albicans pneumonia, however, may profit from the lower toxicity of fluconazole therapy. Since mortality even of treated Candida pneumonia remains high, preventive measures are of particular interest. Risk factors for candidaemia have been identified (e.g. neutropaenia, mechanical ventilation) and may serve to guide in the initiation of preventive treatment for Candida pneumonia.
No takes yet. Share an insight, caveat, or question.
Bauer et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: